


Total Synthesis of the Sphingolipid Biosynthesis Inhibitor Fumonisin B

Claney L. Pereira, Yi-Hung Chen, and Frank E. McDonald

J. Am. Chem. Soc., **2009**, 131 (17), 6066-6067 • DOI: 10.1021/ja9009265 • Publication Date (Web): 08 April 2009

Downloaded from <http://pubs.acs.org> on May 4, 2009



More About This Article

Additional resources and features associated with this article are available within the HTML version:

- Supporting Information
- Access to high resolution figures
- Links to articles and content related to this article
- Copyright permission to reproduce figures and/or text from this article

[View the Full Text HTML](#)



ACS Publications
 High quality. High impact.

Total Synthesis of the Sphingolipid Biosynthesis Inhibitor Fumonisin B₁

Claney L. Pereira, Yi-Hung Chen, and Frank E. McDonald*

Department of Chemistry, Emory University, Atlanta, Georgia 30322

Received February 5, 2009; E-mail: fmcdona@emory.edu

Fumonisin B₁ (**1**, Figure 1) is the primary mycotoxin produced by the fungus *Fusarium verticillioides*, a common contaminant of corn and corn products.^{1,2} The fumonisin-induced “moldy corn poisoning” syndrome is fatal to horses and pigs³ and in humans is associated with esophageal cancer and neural tube birth defects.⁴ The similarity of some structural elements of fumonisins with sphingoid bases and the biological activity of fumonisins as sphingolipid biosynthesis inhibitors, specifically ceramide-synthase-mediated conversion of sphingoid bases to ceramides (*N*-acyl derivatives), suggests a biosynthetic relationship between the fumonisin and sphingolipid classes of natural products.⁵ Although **1** exhibits nephrotoxicity and promotes liver cancer in rats,⁶ hydrolysis of the tricarballylic esters attached to O14 and O15 provides a compound **2** that is less toxic in cell culture.⁷ However, this hydrolyzed form is *N*-acylated by ceramide synthase in vivo and in vitro to provide the *N*-palmitoyl derivative **3**, which is more cytotoxic to HT29 (human colon cancer) cells than fumonisin B₁.⁸ Simpler congeners of fumonisins have been synthesized, including the 10-deoxy compound fumonisin B₂⁹ as well as the hydrolyzed form **2**,¹⁰ but a synthesis of the most complex fumonisin, **1**, has not been previously described.¹¹ In this communication, we present the first total synthesis of fumonisin B₁ by a convergent approach that links the two functionality-rich sectors at the C9–C10 bond.

Our synthesis of the C1–C9 sector began with stereospecific allylic transfer from the camphor-derived reagent **4** to the alkynyl aldehyde **5**,¹² providing the homoallylic alcohol **6** with complete control of the chirality at the C5 alcohol as well as cis alkene selectivity (Scheme 1).¹³ Vanadium-catalyzed hydroxyl-directed epoxidation¹⁴ to **7** was followed by Mitsunobu inversion to form **8** with the correct C5 stereochemistry.¹⁵ Introduction of the azide was achieved with modest selectivity at C2 using the chelating reagent Ti(O-*i*-Pr)₂(N₃)₂,¹⁶ giving azidodiol **9** as the major regioisomer. The C1–C9 sector **10** was then completed by revealing the terminal alkyne and then protecting the two hydroxyls as benzyl ethers.

The key step in the construction of the C10–C20 sector was a stereospecific allylic transfer reaction of our own design¹⁷ that combined the deconjugative aldol product **11**¹⁸ with chiral nonracemic aldehyde **12**¹⁹ in the presence of TMSOTf (Scheme 2). This transformation provided the core structure **13** having the stereochemistry of the C14 alcohol and trans alkene expected from 2-oxonia Cope






Figure 1. Fumonisin B₁ (**1**) and derivatives **2** and **3**.

Scheme 1. Synthesis of the C1–C9 Sector^a



^a Conditions: (a) cat. CSA, CH₂Cl₂ (70% yield, >95:5 er, cis alkene only); (b) cat. VO(acac)₂, *t*-BuOOH, CH₂Cl₂, 0 °C (73% yield, 10:1 dr); (c) Ph₃P, DIAD, HOAc (87% yield); (d) K₂CO₃, MeOH (85% yield); (e) Ti(O-*i*-Pr)₂(N₃)₂, benzene, 80 °C (47% yield of **9** + 17% yield of the C3–azide regioisomer); (f) Bu₄NF, THF (84% yield); (g) NaH, BnBr, THF/DMF (85% yield).


Scheme 2. Preparation of the C10–C20 Core via Allylic Transfer^a



^a Conditions: (a) TMSOTf, CH₂Cl₂ (61% yield, >95:5 dr, trans alkene only); (b) 2-benzyloxy-*N*-methylpyridinium triflate, MgO, PhCF₃ (66% yield); (c) MeMgBr, cat. CuI, cat. (*R*)-tol-BINAP, MTBE, –20 °C (69% yield); (d) BCl₃, CH₂Cl₂ (88% yield); (e) Me₂C(OMe)₂, cat. TsOH (80% yield); (f) Me(Me-O)NH-HCl, *i*-PrMgCl, THF (83% yield); (g) LiAlH₄, THF (71% yield).

rearrangement.²⁰ After benzylation of the C14 alcohol under neutral conditions,²¹ catalytic asymmetric conjugate addition of methylmagnesium bromide afforded the ester **14**.²² In order to selectively deblock the C14,C15-diol at a late stage of the synthesis, the benzyl ethers were replaced by the acetone in **15**.²³ The ester of **15** was converted into the Weinreb amide **16** as well as the primary alcohol **17**, which provided spectroscopic correlation with an intermediate in Kishi's synthesis of fumonisin B₂ (10-deoxy-**1**).⁹

The 20-carbon chain of fumonisin B₁ was then coupled from the lithium acetylide derived from **10** and the Weinreb amide **16** (Scheme 3).²⁴ The C10 stereochemistry was set by enantioselective reduction²⁵ of alkynyl ketone **18**, which after benzyl ether formation and acid-catalyzed acetone removal afforded the C14,C15-diol **19**.²⁶ Esterification of the two hydroxyl groups with tricarballylic acid dibenzyl ester (**20**)²⁷ and global hydrogenation of the azide, the alkyne, and the benzylic ethers and esters afforded **1**, whose spectroscopic characteristics matched

Scheme 3. Syntheses of Fumonisin B₁ (**1**) and Hydrolyzed Fumonisin B₁ (**2**)^a

^a Conditions: (a) **10**, *n*-BuLi, THF, then **16** or **21** (65% yield from **16**, 76% yield from **21**); (b) (*R*)-CBS, catecholborane (71–75% yield, 9:1 dr); (c) NaH, BnBr, THF/DMF (86% yield); (d) Amberlite-120 H⁺, MeOH (80% yield); (e) **20**, EDCl, DMAP, CH₂Cl₂ (71% yield); (f) H₂, Pd(OH)₂/C, *t*-BuOH/THF/HCl (45% yield); (g) H₂, Pd(OH)₂/C, MeOH (94% yield); (h) Ac₂O, Et₃N, DMAP, CH₂Cl₂ (56% yield).

those of a commercial fumonisin B₁ sample. Furthermore, our synthetic material inhibited sphingolipid biosynthesis in a manner similar to that of commercial fumonisin B₁.²⁸

The absence of tricarballylic esters in hydrolyzed fumonisin B₁ (**2**) allowed an efficient protective group regime in which the dibenzyl ether **21** (obtained in one step from ester **14**) was similarly coupled with terminal alkyne **10**, after which enantioselective ketone reduction and global hydrogenation provided **2**, which was further characterized as the known hexaacetyl derivative **22**.¹⁰

In conclusion, we have accomplished the first total synthesis of fumonisin B₁ (**1**) by utilizing two variations on stereoselective allylic transfer methodology. Our synthesis of hydrolyzed fumonisin B₁ (**2**) also provides the starting point for explorations into structure–activity relationships of fumonisin analogues as potential anticancer agents.²⁹

Acknowledgment. We thank Prof. Alfred H. Merrill, Jr. (Georgia Institute of Technology School of Biology) and Dr. Ronald T. Riley (USDA) for validating the biological activity of our synthetic fumonisin B₁. We also acknowledge the use of shared instrumentation provided by the National Institutes of Health, the National Science Foundation, the Georgia Research Alliance, and the University Research Committee of Emory University.

Supporting Information Available: Experimental procedures and spectroscopic characterization of all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- (1) (a) Bezuidenhout, S. C.; Gelderblom, W. C. A.; Gorst-Allman, C. P.; Horak, R. M.; Marasas, W. F. O.; Spiteller, G.; Vleggaar, R. *J. Chem. Soc., Chem. Commun.* **1988**, 743. (b) Cawood, M. E.; Gelderblom, W. C. A.; Vleggaar, R.; Behrend, Y.; Thiel, P. G.; Marasas, W. F. O. *J. Agric. Food Chem.* **1991**, 39, 1958.
- (2) (a) Hoye, T. R.; Jimenez, J. I.; Shier, W. T. *J. Am. Chem. Soc.* **1994**, 116, 9409. (b) Boyle, C. D.; Kishi, Y. *Tetrahedron Lett.* **1995**, 36, 4579. (c) Boyle, C. D.; Kishi, Y. *Tetrahedron Lett.* **1995**, 36, 5695. (d) Shier, W. T.; Abbas, H. K.; Badria, F. A. *Tetrahedron Lett.* **1995**, 36, 1571. (e) Poch, G. K.; Powell, R. G.; Plattner, R. D.; Weisleder, D. *Tetrahedron Lett.* **1994**, 35, 7707. (f) ApSimon, J. W.; Blackwell, B. A.; Edwards, O. E.; Fruchier, A. *Tetrahedron Lett.* **1994**, 35, 7703. (g) Blackwell, B. A.; Edwards, O. E.; ApSimon, J. W.; Fruchier, A. *Tetrahedron Lett.* **1995**, 36, 1973. (h) Hartl, M.; Humpf, H. *Tetrahedron: Asymmetry* **1998**, 9, 1549. (i) Beier, R. C.; Stanker, L. H. *Arch. Environ. Contam. Toxicol.* **1997**, 33, 1.
- (3) (a) Thiel, P. G.; Shephard, G. S.; Sydenham, E. W.; Marasas, W. F. O.; Nelson, P. E.; Wilson, T. M. *J. Agric. Food Chem.* **1991**, 39, 109. (b) Harrison, L. R.; Colvin, B. M.; Green, J. T.; Newman, L. E.; Cole, J. R. *J. Vet. Diagn. Invest.* **1990**, 2, 217.
- (4) (a) Rhedder, J. P.; Marasas, W. F. O.; Thiel, P. G.; Sydenham, E. W.; Shephard, G. S.; Van Schalkwyk, D. *J. Phytopathology* **1992**, 82, 353. (b) Sadler, T. W.; Merrill, A. H.; Stevens, V. L.; Sullards, M. C.; Wang, E.; Wang, P. *Teratology* **2002**, 66, 169. (c) Hendricks, K. *Epidemiology* **1999**, 10, 198.
- (5) Wang, E.; Norred, W. P.; Bacon, C. W.; Riley, R. T.; Merrill, A. H. *J. Biol. Chem.* **1991**, 266, 14486.

- (6) (a) Gelderblom, W. C. A.; Kriek, N. P. J.; Marasas, W. F. O.; Thiel, P. G. *Carcinogenesis* **1991**, 12, 1247. (b) Marasas, W. F. O. *Environ. Health Perspect. Suppl.* **2001**, 109, 239.
- (7) Humpf, H. U.; Schmelz, E. M.; Meredith, F. I.; Vesper, H.; Vales, T. R.; Wang, E.; Menaldino, D. S.; Liotta, D. C.; Merrill, A. H. *J. Biol. Chem.* **1998**, 273, 19060.
- (8) Seiferlein, M.; Humpf, H.-U.; Voss, K. A.; Sullards, M. C.; Allegood, J. C.; Wang, E.; Merrill, A. H. *Mol. Nutr. Food Res.* **2007**, 51, 1120.
- (9) Shi, Y.; Peng, L. F.; Kishi, Y. *J. Org. Chem.* **1997**, 62, 5666.
- (10) Gurjar, M. K.; Rajendran, V.; Rao, B. V. *Tetrahedron Lett.* **1998**, 39, 3803.
- (11) For the synthesis of the related AAL toxins, see: Oikawa, H.; Yamawaki, D.; Kagawa, T.; Ichihara, A. *Tetrahedron Lett.* **1999**, 40, 6621.
- (12) Layton, M. E.; Morales, C. A.; Shair, M. D. *J. Am. Chem. Soc.* **2002**, 124, 773.
- (13) Lee, C. K.; Lee, C. A.; Tan, K.; Loh, T. *Org. Lett.* **2004**, 6, 1281.
- (14) Mihelich, E. D.; Daniels, K.; Eickhoff, D. J. *J. Am. Chem. Soc.* **1981**, 103, 7690.
- (15) Mitsunobu, O. *Synthesis* **1981**, 1.
- (16) Caron, M.; Carlier, P. R.; Sharpless, K. B. *J. Org. Chem.* **1988**, 53, 5187.
- (17) For our previous work in this area, see: Chen, Y.-H.; McDonald, F. E. *J. Am. Chem. Soc.* **2006**, 128, 4568.
- (18) (a) Kende, A. S.; Toder, B. H. *J. Org. Chem.* **1982**, 47, 163. (b) Evans, D. A.; Sjogren, E. B.; Bartroli, J.; Dow, R. L. *Tetrahedron Lett.* **1986**, 27, 4957.
- (19) **12** was synthesized in five steps from 2-hepten-1-ol: (a) Ti(O-*i*-Pr)₄, L-DIPT, *t*-BuOOH (87%); (b) Me₃Al (75%); (c) PhCH(OMe)₂, CSA (74%); (d) DIBAL (95%); (e) IBX (83%). See the Supporting Information for details.
- (20) For pioneering work in this area, see: (a) Sumida, S.; Ohga, M.; Mitani, J.; Nokami, J. *J. Am. Chem. Soc.* **2000**, 122, 1310. (b) Nokami, J.; Ohga, M.; Nakamoto, H.; Matsubara, T.; Hussain, I.; Kataoka, K. *J. Am. Chem. Soc.* **2001**, 123, 9168. (c) Cheng, H.-S.; Loh, T.-P. *J. Am. Chem. Soc.* **2003**, 125, 4990. (d) Nokami, J.; Nomiyama, K.; Shafi, S. M.; Kataoka, K. *Org. Lett.* **2004**, 6, 1261.
- (21) Poon, K. W. C.; Dudley, G. B. *J. Org. Chem.* **2006**, 71, 3923.
- (22) (a) Wang, S.-Y.; Lum, T.-K.; Ji, S.-J.; Loh, T.-P. *Adv. Synth. Catal.* **2008**, 350, 673. (b) Lum, T.-K.; Wang, S.-Y.; Loh, T.-P. *Org. Lett.* **2008**, 10, 761.
- (23) (a) Xia, J.; Hui, Y. Z. *Tetrahedron: Asymmetry* **1997**, 8, 3019. (b) Xie, Z. F.; Suemune, H.; Sakai, K. *J. Chem. Soc., Chem. Commun.* **1988**, 612.
- (24) Shin, Y.; Fournier, J.; Bruckner, A.; Madiraju, C.; Balachandran, R.; Raccor, B. S.; Edler, M. C.; Hamel, E.; Sikorski, R. P.; Vogt, A.; Day, B. W.; Curran, D. P. *Tetrahedron* **2007**, 63, 8537.
- (25) (a) Corey, E. J.; Bakshi, R. K. *Tetrahedron Lett.* **1990**, 31, 611. (b) Helal, C. J.; Magriotis, P. A.; Corey, E. J. *J. Am. Chem. Soc.* **1996**, 118, 10938.
- (26) Ravikumara, K. S.; Farquhar, D. *Tetrahedron Lett.* **2002**, 43, 1367.
- (27) **20** was synthesized in three steps from but-3-enoyloxazolidinone (for which see: Harnat, N. J. S.; Mangani, S.; Perrotta, E.; Giannotti, D.; Nannicini, R.; Altamura, M. *Tetrahedron Lett.* **2000**, 41, 1261.): (a) LHMDs, benzyl bromoacetate (68%); (b) BnOLi (80%); (c) NaIO₄, cat. RuCl₃–H₂O (91%). See the Supporting Information for details.
- (28) Our synthetic fumonisin B₁ showed ~50% inhibition of ¹³C-palmitate incorporation into the sphingoid base backbone of ceramide in RAW264.7 cells when added at 0.1 μM, which is near the K_i for ceramide synthase: Merrill, A. H. (Georgia Institute of Technology); Riley, R. T. (USDA). Private communication.
- (29) For studies of aminodiols compounds similar to the C2–C5 region of fumonisin B₁, see: (a) Menaldino, D. S.; Bushnev, A.; Sun, A.; Liotta, D. C.; Symolon, H.; Desai, K.; Dillehay, D. L.; Peng, Q.; Wang, E.; Allegood, J.; Trotman-Pruett, S.; Sullards, M. C.; Merrill, A. H., Jr. *Pharmacol. Res.* **2003**, 47, 373. (b) Wiseman, J. M.; McDonald, F. E.; Liotta, D. C. *Org. Lett.* **2005**, 7, 3155; Errata: *Org. Lett.* **2007**, 9, 2959.

JA9009265